BETA BIONICS INC (BBNX)
Health Care · medical devices / diabetes care · NASDAQ
Beta Bionics is a medical technology company developing automated insulin delivery systems to simplify diabetes management and improve patient outcomes.
What BETA BIONICS INC does
Beta Bionics is a medical technology company focused on the development and commercialization of automated insulin delivery systems for the management of diabetes. The company's primary technology is designed to simplify insulin delivery through automated control, with the goal of improving glycemic outcomes for individuals with diabetes.
Themes: diabetes management, automated insulin delivery, medical technology
Fundamentals
- Price$19.05 as of 2026-08-21 close
- Market cap$857M as of 2026-08-21
- 1-year return+12.8% 2025-08-21 close $16.89 → 2026-08-21 close $19.05
- P/En/a negative earnings
- Net margin-61.3% as of 2026-08-24
- Gross margin+58.3% as of 2026-08-24
- ROE-26.3% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+94.1% as of 2026-08-24
- Revenue CAGR (3y)+189.1% SEC XBRL
- Beta1.09 as of 2026-08-24
- Last reported earnings2026-07-29 SEC EDGAR Form 8-K (Item 2.02)
How BBNX compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How BETA BIONICS INC looks technically
BETA BIONICS INC (BBNX) is trading 7.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 112 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 9 trading days ago (its momentum flipped positive). It made a new 20-day high about 3 trading days ago. It is 41.8% below its highest point of the past year. Trading volume is unusually light — only about 36% of its 30-day average.
Trend
9
| Distance from the 200-day | it is trading 7.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +7.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $16.11 | $16.11 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $17.68 | $17.68 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 31 calendar days ago — the swings before that are what the structure reading is measured on | 31 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 15. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 112 trading days ago — a "death cross", a bearish long-term signal | 112 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 7.8% above | +7.8% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control | 27.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30) | 62.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($13.33 to $20.73) — its "stochastic" reading is 77 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 77.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 9 trading days ago (its momentum flipped positive) | 9 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $32.71 | $32.71 |
|---|---|---|
| From the 52-week high | it is 41.8% below its 52-week high (its highest price of the past year) | -41.8% |
| Above the 52-week low | it is 116.5% above its 52-week low (its lowest price of the past year) | +116.5% |
| Below the 52-week high | it is 41.8% below its highest point of the past year | 41.8% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $32.71 (set on 2025-11-26) | $32.71 |
| Given back of the 52-week move | over the past year its closes ranged ($8.86 to $31.99), and it has recovered roughly a third of its fall from last year’s high — 44% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $23.15 to $23.89. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 44.1% |
| From the all-time high | it is 41.8% below its all-time high | -41.8% |
| Nearest price level | it is trading 15.7% above a support level at $16.06 — a price it turned at twice since 2025-05-20, most recently on 2026-01-13. Since 2025-01-30 it has 5 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -15.7% |
| All-time low | its lowest closing price on record is $8.80 (set on 2026-04-10) | $8.80 |
| Above the all-time low | it is 116.5% above its all-time low | +116.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 87% of the past ~6 months) | 87th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.25 between its high and its low — about 6.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.25 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $12.21 and $20.60 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $12.21 – $16.40 – $20.60 |
| Typical daily range (% of price) | its price moves about 6.6% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.6% |
| Stretch from the 200-day average | it is trading 1.1 daily ranges above its 200-day average price (7.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 36% of its 30-day average | 0.36× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 1.1% since the prior reading | +1.1% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | 6 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 6 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.1% |
|---|---|---|
| Open gap | it gapped 18.9% above the previous close 51 sessions ago and has not traded back through the level it left behind at 11.82 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +18.9% |
| Gap filled | a 2.2% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -4.8% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 5.8 percentage points (the stock gained 8.1% while the market gained 2.3%) | +5.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 76.5 percentage points (the stock gained 79.5% while the market gained 3.1%) | +76.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 28.0 percentage points (the stock gained 39.1% while the market gained 11.1%) | +28.0% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 7.7 percentage points (the stock gained 12.8% while the market gained 20.5%) | -7.7% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: a "death cross" — its 50-day average is below its 200-day — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 18% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 14.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +18.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 32% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $14.46 — a volume-weighted average of daily closes over 150 sessions, not a true tick-by-tick VWAP. | +31.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 18% above the average price paid since it last reported on 2026-07-29 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $16.08 — a volume-weighted average of daily closes over 18 sessions, not a true tick-by-tick VWAP. | +18.5% |
Price levels it has turned at before
BBNX last closed at $19.05 on 2026-08-21. Since 2025-01-30 it has turned at 5 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $16.06 | Support | 15.7% below the last close | turned there twice · 2025-05-20 to 2026-01-13 |
| $15.64 | Support | 17.9% below the last close | turned there twice · 2025-05-08 to 2026-02-10 |
| $24.34 | Resistance | 27.8% above the last close | turned there twice · 2025-02-07 to 2025-11-06 |
| $13.70 | Support | 28.1% below the last close | turned there twice · 2025-03-10 to 2025-07-29 |
| $27.86 | Resistance | 46.3% above the last close | turned there twice · 2025-12-02 to 2025-12-16 |
| $32.52 | Resistance | 70.7% above the last close | turned there three times · 2025-11-26 to 2026-01-08 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $15.00.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $15.61 and $16.98 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 3 trading days, since 2026-08-19.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · Analyst price target recently RAISED | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.64 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$20.31 range $14.00 – $30.40; median $20.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for BBNX
- Consensus EPS estimate-$0.51 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on third-party manufacturers and single-source suppliers for critical product components.","Ability to maintain regulatory approval and comply with evolving US regulatory requirements.","Market acceptance and the ability to compete against established diabetes management companies."]
What changed in the latest 10-Q
AI-assisted comparison of BBNX's 10-Q filed 2026-04-21 against the prior one filed 2025-10-28.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to Annual Report on Form 10-K for year ended December 31, 2025 (newer filing filed 2026-04-21)
- Reference to 'both our Annual Report on Form 10-K for the year ended December 31, 2025 and in this Quarterly Report' for Risk Factors section (newer filing)
- Statement that 'Diabetes is a chronic condition that requires ongoing insulin management' (newer filing)
- Removal of detailed medical description of T1D as autoimmune disorder attacking beta cells (present in older, absent in newer)
- Updated T1D population figure to 'approximately 1.9 million people' (newer filing, from 1.8 million in older)
- Updated iLet adoption from MDI: '71% of the iLet's adoption during the three months ended March 31, 2026' (newer filing, compared to '67%' for nine months ended September 30, 2024 in older)
- Removal of detailed explanation of iCGM technology description ('wearable device that works by inserting a small sensor...') present in older filing
- Removed:
- Description of T1D as 'an autoimmune disorder that often develops during childhood or adolescence, but can occur at any age, and arises from a person's immune system attacking and destroying the insulin-producing beta cells in the pancreas' (present in older, removed in newer)
- Statement that diabetes 'is a serious, chronic and often lifelong condition with no known cure' and description of hyperglycemia complications (older filing)
- Detailed explanation: 'These systems require PWD to set and to periodically adjust several insulin pump parameters, to quantify daily carbohydrate intake, and to frequently calculate proper doses of insulin' (older filing)
- Statement about complexity limiting uptake 'to a subset of PWD and to subspecialty healthcare providers (HCPs)' (older filing)
- Detailed explanation of data sources: 'This is based on our internal estimates factoring epidemiologic data from government and leading industry organizations such as the CDC...and aggregated by third-party data service providers' (older filing)
- Detailed iCGM technology description: 'An iCGM is a wearable device that works by inserting a small sensor under the skin into fatty tissue and tracks blood sugar levels in real time. The sensor measures glucose levels in the interstitial fluid and sends the information to a receiver, smartphone or insulin pump. The user can view their glucose levels, trends and to what degree their levels are rising or falling. The iCGM is a crucial component of AID systems, and by partnering with these leading global iCGM platforms, we believe we leverage all of the benefits that these CGMs offer in an elegant solution for PWD.' (older filing)
- Reworded:
- Changed 'our2024 Annual Report filed with the SEC' (older) to 'our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC' (newer)
- Changed 'represents a significant advancement over currently available insulin delivery options' (newer) from 'marks a significant advancement over other insulin delivery technologies' (older)
- Changed 'a simplified experience' (newer) from 'a vastly simplified experience' (older)
- Removed detailed paragraph about adaptive closed-loop algorithms removing manual adjustments requirement (older filing contained this; newer is truncated but appears more streamlined)
- Changed reference period from 'through nine months ended September 30, 2025 and 2024' (older) to 'during the three months ended March 31, 2026 and 2025' (newer)
- Notes:
- Newer filing text appears truncated at the end (ends mid-sentence regarding DME reimbursement), limiting full comparison of sections beyond the visible text
- Comparison is limited to the portions of MD&A provided; cannot assess changes in other subsections not included
- Older filing reference period is 'nine months ended September 30' while newer filing uses 'three months ended March 31', making adoption percentages not directly comparable across same timeframe
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 13 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 13 sells ($895960) — 6 selling insiders
- Last 180 days0 buys · 16 sells ($936978) — 7 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-29. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about BBNX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding BBNX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 4,065,323
- Reported value $40,734,537
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
BBNX had 7,604,900 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
BBNX had 16.9% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.02 days to cover at the same settlement.
- Reported short interest (shares) 7,604,900
- Short interest (% of shares outstanding) 16.9%
- Prior settlement (shares) 6,609,679
- Reported change 15.06%
- Days to cover (reported) 6.02
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BBNX vs…
Frequently asked questions
What does BETA BIONICS INC (BBNX) do?
Beta Bionics is a medical technology company focused on the development and commercialization of automated insulin delivery systems for the management of diabetes. The company's primary technology is designed to simplify insulin delivery through automated control, with the goal of improving glycemic outcomes for individuals with diabetes.
What sector is BETA BIONICS INC (BBNX) in?
BETA BIONICS INC (BBNX) is classified in the Health Care sector. Its industry is medical devices / diabetes care. It trades on NASDAQ.
Who are BETA BIONICS INC's (BBNX) competitors?
Notable peers of BETA BIONICS INC (BBNX) include DexCom, Insulet, Medtronic, Tandem Diabetes Care and Abbott Laboratories. This peer set is informational only — not financial advice.
Is BETA BIONICS INC (BBNX) overbought or oversold right now?
BETA BIONICS INC (BBNX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 63, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BBNX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.